LLY NYSE
Eli Lilly and Company
1W: -0.1%
1M: +8.2%
3M: +5.9%
YTD: +18.9%
1Y: +55.5%
3Y: +122.8%
5Y: +450.9%
$1,281.91
+2.77 (+0.22%)
Weekly Expected Move ±4.4%
$1162
$1218
$1273
$1329
$1385
Credit Risk of going bust: lower than 84% of companies Debt: 4.4% of company value Bonds: $1.28B held by 465 funds, 44 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $5.05 (down 99.6%), Eli Lilly and Company would be worth roughly what it owes.
Total debt $54.91B against a stock market value of $1.21T.
Distance to default 10.87 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.98B (short-term plus half of long-term), stock volatility 34.6%; Altman Z 8.57. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $5.05 (down 99.6%), Eli Lilly and Company would be worth roughly what it owes.
Total debt $54.91B against a stock market value of $1.21T.
Distance to default 10.87 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.98B (short-term plus half of long-term), stock volatility 34.6%; Altman Z 8.57. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships0
As Filer
counterparties named
17
As Counterparty
mentioned by others
2021-12-13
Earliest Filing
2026-03-31
Latest Filing
Mentioned As Counterparty
17 mentionsOther companies that named LLY in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals plc | target | Parent company acquiring Centessa Pharmaceuticals plc via a scheme of arrangement | 2026-03-31 | View |
| VTYX Ventyx Biosciences, Inc. | target | Acquired Ventyx Biosciences, Inc. in a merger transaction consummated on March 4, 2026. | 2026-03-04 | View |
| RNAM Avidity Biosciences, Inc. | partner | Counterparty to collaboration agreements retained by SpinCo | 2026-02-27 | View |
| RNA Atrium Therapeutics, Inc. | partner | Collaboration partner whose agreement was transferred to the spun-off company. | 2026-02-27 | View |
| VTYX Ventyx Biosciences, Inc. | target | Parent company acquiring Ventyx Biosciences, Inc. in a merger transaction. | 2026-01-07 | View |
| ZURA Zura Bio Ltd | licensee | Holds a license agreement with ZB17 LLC relevant to royalty payments under the new Athanor Agreement. | 2026-01-02 | View |
| MGTX MeiraGTx Holdings plc | partner | Strategic collaboration and license agreement for genetic medicines in ophthalmology | 2025-11-10 | View |
| VIVS ORGANOVO HOLDINGS, INC. | target | Acquired Organovo's FXR program and related assets for $10 million upfront plus potential milestones. | 2025-03-26 | View |
| VIVS ORGANOVO HOLDINGS, INC. | target | Purchased Organovo Holdings' FXR program and related assets for $10 million upfront plus potential milestones. | 2025-02-25 | View |
| ACRS Aclaris Therapeutics, Inc. | partner | Holds the existing license agreement with Aclaris Therapeutics, Inc. for OLUMIANT, from whom royalties are being purchas | 2024-07-16 | View |
| BEAM Beam Therapeutics Inc. | target | Acquired opt-in rights to Verve's base editing programs for cardiovascular disease and purchased Beam stock. | 2023-10-31 | View |
| DERM Journey Medical Corp | customer | Parent company of Dermira, original licensor of Qbrexza | 2023-09-06 | View |
| DTIL PRECISION BIOSCIENCES INC | partner | Parent company of Prevail Therapeutics Inc. that previously held the original development and license agreement with Pre | 2023-07-06 | View |
| ZURA Zura Bio Ltd | partner | Entered into a License, Development and Commercialization Agreement for ZB-106 and an Equity Grant Agreement for 1,000,0 | 2023-05-03 | View |
| ZURA Zura Bio Ltd | partner | Counterparty to the JATT Equity Grant Agreement and Lilly Lock-Up Agreement. | 2023-03-24 | View |
| ZURA JATT Acquisition Corp | partner | Pharmaceutical company granting IP license to Z33 and receiving equity from JATT | 2022-12-12 | View |
| FHTX Foghorn Therapeutics Inc. | partner | Entered into a collaboration agreement and stock purchase agreement for joint development, licensing, and equity investm | 2021-12-13 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-05-20 | Other Events; Exhibits | View | |
| 2026-05-07 | Shareholder Vote | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-02-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-20 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-08 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-19 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-09 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-08-16 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-08-14 | Other Events; Financial Statements and Exhibits | View | |
| 2024-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR